Incretin Atlas › Trials › BGM0504 phase 3 (obesity)
BGM0504 phase 3 (obesity)
BGM0504 · obesity
Design
- Molecule(s)
- BGM0504
- Population
- obesity
- Phase
- 3
- Duration
- 52 weeks
Results by arm
| Arm | Population | Weeks | n | Weight, efficacy | Weight, treatment-policy | HbA1c, pp | AE discontinuation, % | Any discontinuation, % | Nausea, % | Vomiting, % | SAE, % | SBP, mmHg | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BGM0504 15 mg | obesity china | 52 | — | — | −19.2 % vs −3.1 % Δ −16.1 pp | — | 0.7 | — | — | — | — | — | verified |
| BGM0504 10 mg | obesity china | 52 | — | — | −17.3 % vs −3.1 % Δ −14.2 pp | — | 1.2 | — | — | — | — | — | verified |
| BGM0504 5 mg | obesity china | 52 | — | — | −14.3 % vs −3.1 % Δ −11.2 pp | — | 1.7 | — | — | — | — | — | verified |
Weight: percent change from baseline, drug vs placebo or comparator, Δ = difference in percentage points. Efficacy estimand = effect while on treatment (hypothetical strategy); treatment-policy = all randomised participants regardless of adherence (ITT). AE discontinuation = stopped study drug for any adverse event. Hover a status for its definition.
Verbatim quotes from the source (6)
- BGM0504 15 mg · weight_tp · Results
15 mg: −19.19% (95% CI: −20.63 to −17.76), corresponding to −18.26 kg (95% CI: −19.66 to −16.86)
- BGM0504 15 mg · ae_dc · HKEX filing
BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
- BGM0504 10 mg · weight_tp · Results
10 mg: −17.27% (95% CI: −18.67 to −15.88), corresponding to −16.47 kg (95% CI: −17.85 to −15.09)
- BGM0504 10 mg · ae_dc · HKEX filing
BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
- BGM0504 5 mg · weight_tp · Results
5 mg: −14.31% (95% CI: −15.69 to −12.93), corresponding to −13.48 kg (95% CI: −14.83 to −12.13)
- BGM0504 5 mg · ae_dc · HKEX filing
BGM0504 注射液治疗 52 周各剂量组因不良事件导致的终止治疗比例分别为 1.7%、1.2%和 0.7%
Primary sources
- Linong Ji et al. Efficacy and safety of BGM0504 in Chinese patients with overweight or obesity: a multicentre, randomised, double-blind, placebo-controlled Phase 3 trial. Abstract LBA 37. EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. [Session: LBA OP 07 Incretins: more on signalling, trials and real-world evidence]
- BrightGene. 博瑞医药 (688166.SH) 自愿披露关于BGM0504注射液减重适应症III期临床试验数据的公告 (2026-029) [HKEX filing]. 2026-05-05. Available from: http://static.cninfo.com.cn/finalpage/2026-05-06/1225277468.PDF
- EASD 2026 Annual Meeting; 2026 Sep 29–Oct 3; Milan. Abstract easd66778.
How to cite this page
Medical Adviser's Group. Incretin Atlas: BGM0504 phase 3 (obesity). Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/bgm0504-phase-3/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.